870853 | ST1326
(R)-3-(3-tetradecylureido)-4-(trimethylammonio)butanoate

ST1326
(R)-3-(3-tetradecylureido)-4-(trimethylammonio)butanoate
ST1326 is a bioactive lipid inhibitor that can temporarily block the activity of enzymes involved in fatty acid synthesis, called carnitine palmitoyltransferase. It has been shown to have anti-tumor progression effects in human leukemia cells.
Application
It’s suggested that ST1326, in treating chronic lymphocytic leukemia (CLL) cells, is a promising addition to anti-CLL drug combinations, targeting leukemia cell activation and proliferation. ST1326 displays significant potential to enhance current CLL therapies, even in cases where drugs lose efficacy on proliferating cells. Notably, it is effective at lower concentrations than common inhibitors and synergizes with ABT-199 and fludarabine.
ST1326 can effectively inhibit FAO (fatty acid oxidation), which leukemia cell lines need for survival. It does this by selectively targeting the CPT1A isoform and inducing mitochondrial dysfunction, triggering the mitochondrial apoptotic pathway. With this action, ST1326 achieves antitumor activity by leading to apoptosis induction in leukemia cell metabolism while sparing normal bone marrow progenitors. Data gathered on primary hematopoietic malignant cells confirmed the FAO inhibition and cytotoxic activity of ST1326, particularly on acute myeloid leukemia cells.
Packaging
Provide life-changing discoveries for the world with ST1326 from Avanti Research in 1mg powder packaging.
CAS Registry Number is a Registered Trademark of the American Chemical Society
Grønningsæter IS, Reikvam H, Aasebø E, Bartaula-Brevik S, Tvedt TH, Bruserud Ø, Hatfield KJ. Targeting Cellular Metabolism in Acute Myeloid Leukemia and The Role of Patient Heterogeneity. Cells. 2020 May 7;9(5):1155. doi: 10.3390/cells9051155. PMID: 32392896; PMCID: PMC7290417.
PubMed ID: 32392896Cheng S, Wang G, Wang Y, Cai L, Qian K, Ju L, Liu X, Xiao Y, Wang X. Fatty acid oxidation inhibitor etomoxir suppresses tumor progression and induces cell cycle arrest via PPARγ-mediated pathway in bladder cancer. Clin Sci (Lond). 2019 Aug 7;133(15):1745-1758. doi: 10.1042/CS20190587. PMID: 31358595.
PubMed ID: 31358595- Certificate of Analysis (Lot No. 870853P-1MG-A-010 and 6262PGA010)
- Certificate of Analysis (Lot No. 870853P-1MG-B-010 and 6262PGB010)
- Certificate of Analysis (Lot No. 870853P-1MG-C-010 and 6262PGC010)
- Certificate of Analysis (Lot No. 870853P-1MG-D-010 and 6262PGD010)
- Certificate of Analysis (Lot No. 870853P-1MG-E-010 and 6262PGE010)
- Certificate of Analysis (Lot No. 870853P-CONF-A-010 and 6262PWA010)
- Certificate of Analysis (Lot No. 870853P-1MG-F-010 and 6262PGF010)
- Certificate of Analysis (Lot No. 870853P-1MG-G-010 and 6262PGG010)
- Certificate of Analysis (Lot No. 870853P-1MG-H-010 and 6262PGH010)
- Certificate of Analysis (Lot No. 870853P-1MG-I-010 and 6262PGI010)
- Certificate of Analysis (Lot No. 870853P-1MG-J-010 and 6262PGJ010)
- Certificate of Analysis (Lot No. 870853P-1MG-K-010 and 6262PGK010)
- Certificate of Analysis (Lot No. 870853P-1MG-L-010 and 6262PGL010)